ResearchMoz

ENT Disorders Market to 2017- Cephalosporins, Quinolones and Macrolides to Replace Older Therapies Due to Anti-Bacterial Resistance

GBI Research
Published Date » 2012-01-01
No. Of Pages » 165

GBI Research, the leading business intelligence provider, has released its latest research, “ENT Disorders Market to 2017- Cephalosporins, Quinolones and Macrolides to Replace Older Therapies Due to Anti-Bacterial Resistance”, which provides in-depth analysis of the unmet needs, drivers and barriers that affect the global ENT disorders therapeutics market. The report analyzes the markets for ENT disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. 

Treatment usage patterns, sales value and annual cost of therapy are forecast until 2017 for key geographies in the five leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers and acquisitions (M&A) and licensing agreements that shape the global markets.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. 

GBI Research’s analysis shows that the ENT disorders market will continue to grow marginally, largely due to the growing population and deteriorating environmental conditions. The prime reasons for the slow growth of the market are the generic domination and the weak product pipelines for all five key indications. 

The global ENT disorders market was estimated to be worth $15.3 billion in 2010, having grown at a compound annual growth rate (CAGR) of 0.7% between 2002 and 2010. By 2017, the global ENT disorders market is forecast to reach $17.2 billion, indicating a CAGR of 1.6% between 2010 and 2017.

The ENT disorders M&A landscape has seen low levels of activity over the last decade, with only 16 deals signed from 2004-2011. The therapeutic area of focus for the M&A deals from 2004-2011 remained highly concentrated for sinusitis. Some deals had multiple ENT disorders as their therapeutic area of focus.

Scope

  • Annualized market data for the ENT disorders market from 2002 to 2010, forecast forward to 2017.
  • Analysis of the leading therapeutic segments, including tonsillitis, sinusitis, rhinitis, otitis media and tracheobronchitis.
  • Analysis of the ENT disorders market in the leading geographies globally, which include the US, the UK, Germany, France, Italy, Spain and Japan.
  • Market characterization of the ENT disorders market, including market size, annual cost of therapy and treatment usage patterns
  • Key drivers and barriers that have a significant impact on the market
  • Coverage of pipeline molecules in the various phases of drug development
  • Competitive benchmarking of leading companies. The key companies studied in this report are Abbott Laboratories, Bayer AG, Eli Lilly, GSK, J&J, Novartis AG, Merck & Co., Pfizer and Sanofi.
  • Key M&A activities and licensing agreements that have taken place between 2004 and mid-2011 in the global ENT disorders market

Reasons to buy

  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
  • Reinforce R&D pipelines by identifying new target mechanisms that can produce first-in-class molecules with more efficiency and better safety.
  • Develop key strategic initiatives by understanding the key focus areas of leading companies.
  • Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.
Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 ENT Disorders Market - Introduction
2.1 GBI Research Report Guidance

3 ENT Disorders Market - Market Overview
3.1 Rising Global Population and Deteriorating Environmental Conditions Drive ENT Disorder Therapeutics
3.2 Gross Maldistribution
3.3 ENT Disorders Marked By Antibiotic Overuse
3.4 Entry of New Players Restricted by the Number of Generics and Stringent FDA Regulations
3.4.1 Ketolides - A New Class of Antibacterials
3.5 Revenue Forecasts
3.6 Annual Cost of Therapy
3.7 Treatment Usage Patterns
3.7.1 Diseased Population
3.7.2 Treatment Seeking Population
3.7.3 Diagnosed Population
3.7.4 Prescription Population
3.8 Drivers and Restraints of the ENT Disorders Market
3.8.1 ENT Disorders Market Drivers
3.8.2 ENT Disorders Market Restraints

4 ENT Disorders Market - Therapeutic Landscape
4.1 Tonsillitis Market
4.1.1 Introduction
4.1.2 Revenue Forecasts
4.1.3 Annual Cost of Therapy
4.1.4 Treatment Flow Algorithm
4.1.5 Treatment Usage Patterns
4.1.6 Profiles of Key Drugs in the Tonsillitis Market
4.1.7 Geographical Segmentation
4.2 Sinusitis Market
4.2.1 Introduction
4.2.2 Revenue Forecasts
4.2.3 Annual Cost of Therapy
4.2.4 Treatment Flow Algorithm
4.2.5 Treatment Usage Patterns
4.2.6 Profiles of Key Drugs in the Sinusitis Market
4.2.7 Geographical Segmentation
4.3 Rhinitis Market
4.3.1 Introduction
4.3.2 Revenue Forecasts
4.3.3 Annual Cost of Therapy
4.3.4 Treatment Flow Algorithm
4.3.5 Treatment Usage Patterns
4.3.6 Profiles of Key Drugs in the Rhinitis Market
4.3.7 Geographical Segmentation
4.4 Otitis Media Market
4.4.1 Introduction
4.4.2 Revenue Forecasts
4.4.3 Annual Cost of Therapy
4.4.4 Treatment Flow Algorithm
4.4.5 Treatment Usage Patterns
4.4.6 Profiles of Key Drugs in the Otitis Media Market
4.4.7 Geographical Segmentation
4.5 Tracheobronchitis Market
4.5.1 Introduction
4.5.2 Revenue Forecasts
4.5.3 Annual Cost of Therapy
4.5.4 Treatment Flow Algorithm
4.5.5 Treatment Usage Patterns
4.5.6 Profiles of Key Drugs in the Tracheobronchitis Market
4.5.7 Geographical Segmentation

5 ENT Disorders Market - Geographical Landscape
5.1 The US
5.1.1 Revenue Forecasts
5.1.2 Annual Cost of Therapy
5.1.3 Treatment Usage Patterns
5.2 Top Five Countries in Europe
5.2.1 Revenue Forecasts
5.2.2 Annual Cost of Therapy
5.2.3 Treatment Usage Patterns
5.3 Japan
5.3.1 Revenue Forecasts
5.3.2 Annual Cost of Therapy
5.3.3 Treatment Usage Patterns

6 ENT Disorders Market - Pipeline Analysis
6.1 Introduction
6.1.1 Research and Development Pipeline - Tonsillitis
6.1.2 Research and Development Pipeline - Sinusitis
6.1.3 Research and Development Pipeline - Rhinitis
6.1.4 Research and Development Pipeline - Otitis Media

7 ENT Disorders Market - Competitive Landscape
7.1 Competitive Profiling
7.1.1 Abbott Laboratories
7.1.2 Bayer AG
7.1.3 GlaxoSmithKline
7.1.4 Johnson & Johnson (J&J)
7.1.5 Merck & Co
7.1.6 Pfizer
7.1.7 Novartis AG
7.1.8 F. Hoffmann-La Roche Ltd.
7.1.9 Sanofi

8 ENT Disorders Market - Strategic Consolidations
8.1 Overview
8.2 ENT Disorders Market M&A Deals
8.2.1 M&A Deals by Geography
8.2.2 Deals by Type
8.2.3 Major M&A Deals
8.3 R&D Licensing Agreements
8.3.1 Deals by Indication
8.3.2 Deals by Geography
8.3.3 MerLion Pharmaceuticals Enters Into Licensing Agreement with Alcon Pharmaceuticals for Finafloxacin

9 ENT Disorders Market - Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Primary Research
9.3.4 Geographical Landscape
9.3.5 Pipeline Analysis
9.3.6 Competitive Landscape
9.3.7 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Sources

List of Tables


Table 1: ENT Disorders Market, Global, Revenue ($bn), 2002-2010
Table 2: ENT Disorders Market, Global, Revenue Forecasts ($bn), 2010-2017
Table 3: ENT Disorders Market, Global, Annual Cost of Therapy ($), 2002-2010
Table 4: ENT Disorders Market, Global, Annual Cost of Therapy ($), 2010-2017
Table 5: ENT Disorders Market, Global, Treatment Usage Patterns (million), 2002-2010
Table 6: ENT Disorders Market, Global, Treatment Usage Pattern (million), 2010-2017
Table 7: ENT Disorders Market, Global, Tonsillitis Revenue ($m), 2002-2010
Table 8: ENT Disorders Market, Global, Tonsillitis Revenue Forecasts ($m), 2010-2017
Table 9: ENT Disorders Market, Global, Tonsillitis Annual Cost of Therapy ($), 2002-2010
Table 10: ENT Disorders Market, Global, Tonsillitis Annual Cost of Therapy ($), 2010-2017
Table 11: ENT Disorders Market, Global, Tonsillitis Treatment Usage Patterns (million), 2002-2010
Table 12: ENT Disorders Market, Global, Tonsillitis Treatment Usage Patterns (million), 2010-2017
Table 13: ENT Disorders Market, Global, Tonsillitis, Geographical Segmentation ($m), 2002-2010
Table 14: ENT Disorders Market, Global, Tonsillitis, Geographical Segmentation ($m), 2010-2017
Table 15: ENT Disorders Market, Global, Sinusitis Revenue ($bn), 2002-2010
Table 16: ENT Disorders Market, Global, Sinusitis Revenue Forecasts ($bn), 2010-2017
Table 17: ENT Disorders Market, Global, Sinusitis Annual Cost of Therapy ($), 2002-2010
Table 18: ENT Disorders Market, Global, Sinusitis Annual Cost of Therapy ($), 2010-2017
Table 19: ENT Disorders Market, Global, Sinusitis Treatment Usage Patterns (million), 2002-2010
Table 20: ENT Disorders Market, Global, Sinusitis Treatment Usage Patterns (million), 2010-2017
Table 21: ENT Disorders Market, Global, Sinusitis Market Geographical Segmentation ($m), 2002-2010
Table 22: ENT Disorders Market, Global, Sinusitis Market Geographical Segmentation ($m), 2010-2017
Table 23: ENT Disorders Market, Global, Rhinitis Revenue ($bn), 2002-2010
Table 24: ENT Disorders Market, Global, Rhinitis Revenue Forecasts ($bn), 2010-2017
Table 25: ENT Disorders Market, Global, Rhinitis Annual Cost of Therapy ($), 2002-2010
Table 26: ENT Disorders Market, Global, Rhinitis Annual Cost of Therapy ($), 2010-2017
Table 27: ENT Disorders Market, Global, Rhinitis Treatment Usage Patterns (million), 2002-2010
Table 28: ENT Disorders Market, Global, Rhinitis Treatment Usage Patterns (million), 2010-2017
Table 29: ENT Disorders Market, Global, Rhinitis Market Geographical Segmentation ($m), 2002-2010
Table 30: ENT Disorders Market, Global, Rhinitis Market Geographical Segmentation ($m), 2010-2017
Table 31: ENT Disorders Market, Global, Otitis Media Revenue ($m), 2002-2010
Table 32: ENT Disorders Market, Global, Otitis Media Revenue Forecasts ($m), 2010-2017
Table 33: ENT Disorders Market, Global, Otitis Media Annual Cost of Therapy ($), 2002-2010
Table 34: ENT Disorders Market, Global, Otitis Media Annual Cost of Therapy ($), 2010-2017
Table 35: ENT Disorders Market, Global, Otitis Media Treatment Usage Patterns (million), 2002-2010
Table 36: ENT Disorders Market, Global, Otitis Media Treatment Usage Patterns (million), 2010-2017
Table 37: ENT Disorders Market, Global, Otitis Media Market Geographical Segmentation ($m), 2002-2010
Table 38: ENT Disorders Market, Global, Otitis Media Market Geographical Segmentation ($m), 2010-2017
Table 39: ENT Disorders Market, Global, Tracheobronchitis Revenue ($m), 2002-2010
Table 40: ENT Disorders Market, Global, Tracheobronchitis Revenue Forecasts ($m), 2010-2017
Table 41: ENT Disorders Market, Global, Tracheobronchitis Annual Cost of Therapy ($), 2002-2010
Table 42: ENT Disorders Market, Global, Tracheobronchitis Annual Cost of Therapy ($), 2010-2017
Table 43: ENT Disorders Market, Global, Tracheobronchitis Treatment Usage Patterns (million), 2002-2010
Table 44: ENT Disorders Market, Global, Tracheobronchitis Treatment Usage Patterns (million), 2010-2017
Table 45: ENT Disorders Market, Global, Tracheobronchitis Market Geographical Segmentation ($m), 2002-2010
Table 46: ENT Disorders Market, Global, Tracheobronchitis Market Geographical Segmentation ($m), 2010-2017
Table 47: ENT Disorders Market, Global, Revenue by Geography ($bn), 2002-2010
Table 48: ENT Disorders Market, Global, Revenue Forecasts by Geography ($bn), 2010-2017
Table 49: ENT Disorders Market, The US, Revenue ($bn), 2002-2010
Table 50: ENT Disorders Market, The US, Revenue Forecasts ($bn), 2010-2017
Table 51: ENT Disorders Market, the US, Annual Cost of Therapy ($), 2002-2010
Table 52: ENT Disorders Market, the US, Annual Cost of Therapy ($), 2010-2017
Table 53: ENT Disorders Market, The US, Treatment Usage Pattern (million), 2002-2010
Table 54: ENT Disorders Market, The US, Treatment Usage Patterns (million), 2010-2017
Table 55: ENT Disorders Market, Top Five Countries in Europe, Revenue ($bn), 2002-2010
Table 56: ENT Disorders Market, Top Five Countries in Europe, Revenue Forecasts ($bn), 2010-2017
Table 57: ENT Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2010
Table 58: ENT Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2010-2017
Table 59: ENT Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2002-2010
Table 60: ENT Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2010-2017
Table 61: ENT Disorders Market, Japan, Revenues ($m), 2002-2010
Table 62: ENT Disorders Market, Japan, Revenues ($m), 2010-2017
Table 63: ENT Disorders Market, Japan Annual Cost of Therapy, ($), 2002-2010
Table 64: ENT Disorders Market, Japan Annual Cost of Therapy, ($), 2010-2017
Table 65: ENT Disorders Market, Japan, Treatment Usage Pattern (million), 2002-2010
Table 66: ENT Disorders Market, Japan, Treatment Usage Pattern (million), 2010-2017
Table 67: ENT Disorders Market, Global, Tonsillitis Phase III Clinical Pipeline, 2011
Table 68: ENT Disorders Market, Global, Sinusitis Phase III Clinical Pipeline, 2011
Table 69: ENT Disorders Market, Global, Rhinitis Phase III Clinical Pipeline, 2011
Table 70: ENT Disorders Market, Global, Rhinitis Phase II Clinical Pipeline, 2011
Table 71: ENT Disorders Market, Global, Rhinitis Phase I Clinical Pipeline, 2011
Table 72: ENT Disorders Market, Global, Rhinitis Pre-clinical Pipeline, 2011
Table 73: ENT Disorders Market, Global, Otitis Media, Regulatory Filing and Phase III Clinical Pipeline, 2011

List of Figures


Figure 1: ENT Disorders Market, Global, Revenue Forecasts ($bn), 2002-2017
Figure 2: ENT Disorders Market, Global, Annual Cost of Therapy ($), 2002-2017
Figure 3: ENT Disorders Market, Global, Treatment Usage Patterns (million), 2002-2017
Figure 4: ENT Disorders Market, Global, Diseased Population (million), 2002-2017
Figure 5: ENT Disorders Market, Global, Treatment Seeking Population (million), 2002-2017
Figure 6: ENT Disorders Market, Global, Diagnosis Population (million), 2002-2017
Figure 7: ENT Disorders Market, Global, Prescription Population (million), 2002-2017
Figure 8: ENT Disorders Market, Global, Drivers and Restraints, 2011
Figure 9: ENT Disorders Market, Global, Tonsillitis Revenue Forecasts ($m), 2002-2017
Figure 10: ENT Disorders Market, Global, Tonsillitis Therapeutics Market, Branded and Generic Share, (%), 2010
Figure 11: ENT Disorders Market, Global, Tonsillitis Annual Cost of Therapy ($), 2002-2017
Figure 12: ENT Disorders Market, Global, Tonsillitis, Treatment Flow Algorithm
Figure 13: ENT Disorders Market, Global, Tonsillitis Treatment Usage Patterns (million), 2002-2017
Figure 14: ENT Disorders Market, Global, Tonsillitis Diseased Population (million), 2002-2017
Figure 15: ENT Disorders Market, Global, Tonsillitis Treatment Seeking Population (million), 2002-2017
Figure 16: ENT Disorders Market, Global, Tonsillitis Diagnosis Population (million), 2002-2017
Figure 17: ENT Disorders Market, Global, Tonsillitis Prescription Population (million), 2002-2017
Figure 18: ENT Disorders Market, Global, Tonsillitis Market Segmentation by Geography, (%), 2010 and 2017
Figure 19: ENT Disorders Market, Global, Tonsillitis, Geographical Segmentation ($m), 2002-2017
Figure 20: ENT Disorders Market, Global, Sinusitis Revenue Forecasts ($bn), 2002-2017
Figure 21: ENT Disorders Market, Global, Sinusitis Therapeutics Market, Branded and Generic Share, (%), 2010 and 2017
Figure 22: ENT Disorders Market, Global, Sinusitis Annual Cost of Therapy ($), 2002-2017
Figure 23: ENT Disorders Market, Global, Sinusitis, Treatment Flow Algorithm
Figure 24: ENT Disorders Market, Global, Sinusitis Treatment Usage Patterns (million), 2002-2017
Figure 25: ENT Disorders Market, Global, Sinusitis Diseased Population (million), 2002-2017
Figure 26: ENT Disorders Market, Global, Sinusitis Treatment Seeking Population (million), 2002-2017
Figure 27: ENT Disorders Market, Global, Sinusitis Diagnosed Population (million), 2002-2017
Figure 28: ENT Disorders Market, Global, Sinusitis Prescription Population (million), 2002-2017
Figure 29: ENT Disorders Market, Global, Sinusitis Market Segmentation by Geography, 2010 and 2017
Figure 30: ENT Disorders Market, Global, Sinusitis Market Geographical Segmentation ($bn), 2002-2017
Figure 31: ENT Disorders Market, Global, Rhinitis Revenue Forecasts ($bn), 2002-2017
Figure 32: ENT Disorders Market, Global Rhinitis, Branded and Generic Share, (%), 2010 and 2017
Figure 33: ENT Disorders Market, Global, Rhinitis Annual Cost of Therapy ($), 2002-2017
Figure 34: ENT Disorders Market, Global, Rhinitis, Treatment Flow Algorithm
Figure 35: ENT Disorders Market, Global, Rhinitis Treatment Usage Patterns (million), 2002-2017
Figure 36: ENT Disorders Market, Global, Rhinitis Diseased Population (million), 2002-2017
Figure 37: ENT Disorders Market, Global, Rhinitis Treatment Seeking Population (million), 2002-2017
Figure 38: ENT Disorders Market, Global, Rhinitis Diagnosis Population (million), 2002-2017
Figure 39: ENT Disorders Market, Global, Rhinitis Prescription Population (million), 2002-2017
Figure 40: ENT Disorders Market, Global, Rhinitis Market Segmentation by Geography, 2010 and 2017
Figure 41: ENT Disorders Market, Global, Rhinitis Market Geographical Segmentation ($bn), 2002-2017
Figure 42: ENT Disorders Market, Global, Otitis Media Revenue Forecasts ($m), 2002-2017
Figure 43: ENT Disorders Market, Global, Otitis Media Therapeutics Market, Branded and Generic Share, (%), 2010 and 2017
Figure 44: ENT Disorders Market, Global, Otitis Media Annual Cost of Therapy ($), 2002-2017
Figure 45: ENT Disorders Market, Global, Otitis Media, Treatment Flow Algorithm
Figure 46: ENT Disorders Market, Global, Otitis Media Treatment Usage Patterns (million), 2002-2017
Figure 47: ENT Disorders Market, Global, Otitis Media, Causes (%), 2011
Figure 48: ENT Disorders Market, Global, Otitis Media Diseased Population (million), 2002-2017
Figure 49: ENT Disorders Market, Global, Otitis Media Treatment Seeking Population (million), 2002-2017
Figure 50: ENT Disorders Market, Global, Otitis Media Diagnosed Population (million), 2002-2017
Figure 51: ENT Disorders Market, Global, Otitis Media Prescription Population (million), 2002-2017
Figure 52: ENT Disorders Market, Global, Otitis Media Market Segmentation by Geography, (%), 2010 and 2017
Figure 53: ENT Disorders Market, Global, Otitis Media Market Geographical Segmentation ($m), 2002-2017
Figure 54: ENT Disorders Market, Global, Tracheobronchitis Revenue Forecasts ($m), 2002-2017
Figure 55: ENT Disorders Market , Global, Tracheobronchitis Therapeutics Market, Branded and Generic Share (%), 2010 and 2017
Figure 56: ENT Disorders Market, Global, Tracheobronchitis Annual Cost of Therapy ($), 2002-2017
Figure 57: ENT Disorders Market, Global, Tracheobronchitis, Treatment Flow Algorithm
Figure 58: ENT Disorders Market, Global, Tracheobronchitis Treatment Usage Patterns (million), 2002-2017
Figure 59: ENT Disorders Market, Global, Tracheobronchitis Diseased Population (million), 2002-2017
Figure 60:ENT Disorders Market, Global, Tracheobronchitis Treatment Seeking Population (million), 2002-2017
Figure 61: ENT Disorders Market, Global, Tracheobronchitis Diagnosed Population (million), 2002-2017
Figure 62: ENT Disorders Market, Global, Tracheobronchitis Prescription Population (million), 2002-2017
Figure 63: ENT Disorders Market, Global, Tracheobronchitis Market Segmentation by Geography, 2010 and 2017
Figure 64: ENT Disorders Market, Global, Tracheobronchitis Market Geographical Segmentation ($m), 2002-2017
Figure 65: ENT Disorders Market, Global, Market Share by Geography, (%), 2010 and 2017
Figure 66: ENT Disorders Market, Global, Revenue Forecasts by Geography ($bn), 2002-2017
Figure 67: ENT Disorders Market, The US, Revenue Forecasts ($bn), 2002-2017
Figure 68: ENT Disorders Market, the US, Annual Cost of Therapy ($), 2002-2017
Figure 69: ENT Disorders Market, The US, Treatment Usage Pattern (million), 2002-2017
Figure 70: ENT Disorders Market, The US, Diseased Population (million), 2002-2017
Figure 71: ENT Disorders Market, The US, Treatment Seeking Population (million), 2002-2017
Figure 72: ENT Disorders Market, The US, Diagnosed Population (million), 2002-2017
Figure 73: ENT Disorders Market, The US, Prescription Population (million), 2002-2017
Figure 74: ENT Disorders Market, Top Five Countries in Europe, Revenue Forecasts ($bn), 2002-2017
Figure 75: ENT Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2017
Figure 76: ENT Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2002-2017
Figure 77: ENT Disorders Market, Top Five Countries in Europe, Diseased Population (million), 2002-2017
Figure 78: ENT Disorders Market, Top Five Countries in Europe, Treatment Seeking Population (million), 2002-2017
Figure 79: ENT Disorders Market, Top Five Countries in Europe, Diagnosed Population (million), 2002-2017
Figure 80: ENT Disorders Market, Top Five Countries in Europe, Prescription Population (million), 2002-2017
Figure 81: ENT Disorders Market, Japan, Revenues ($m), 2002-2017
Figure 82: ENT Disorders Market, Japan Annual Cost of Therapy, ($), 2002-2017
Figure 83: ENT Disorders Market, Japan, Treatment Usage Pattern (million), 2002-2017
Figure 84: ENT Disorders Market, Japan, Diseased Population (million), 2002-2017
Figure 85: ENT Disorders Market, Japan, Treatment Seeking Population (million), 2002-2017
Figure 86: ENT Disorders Market, Japan, Diagnosis Population (million), 2002-2017
Figure 87: ENT Disorders Market, Japan, Prescription Population (million), 2002-2017
Figure 88: ENT Disorders Market, Global, R&D Pipeline by Indication (%), 2011
Figure 89: ENT Disorders Market, Global, R&D Pipeline by Phase (%), 2011
Figure 90: ENT Disorders Market, Global, R&D Pipeline by Phase in Sinusitis Market (%), 2011
Figure 91: ENT Disorders Market, Global, R&D Pipeline by Phase in Rhinitis Market (%), 2011
Figure 92: ENT Disorders Market, Global, R&D Pipeline by Phase in Otitis Media (%), 2011
Figure 93: ENT Disorders Market, Global, SWOT - Abbott Laboratories, 2011
Figure 94: ENT Disorders Market, Global, SWOT - Bayer AG, 2011
Figure 95: ENT Disorders Market, Global, SWOT - GSK, 2011
Figure 96: ENT Disorders Market, Global, SWOT - Johnson & Johnson, 2011
Figure 97: ENT Disorders Market, Global, SWOT - Merck, 2011
Figure 98: ENT Disorders Market, Global, SWOT - Pfizer, 2011
Figure 99: ENT Disorders Market, Global, SWOT - Novartis, 2011
Figure 100: ENT Disorders Market, Global, SWOT - Roche, 2011
Figure 101: ENT Disorders Market, Global, SWOT- Sanofi, 2011
Figure 102: ENT Disorders Market, Global, M&A Deals by Indication (%), 2004-2011
Figure 103: ENT Disorders Market, Global, Major M&A Deals By Geography (%), 2004-2011
Figure 104: ENT Disorders Market, Global, Major M&A Deals By Type (%), 2004-2011
Figure 105: ENT Disorders Market, Global, Licensing Deals by Indication (%), 2004-2011
Figure 106: ENT Disorders Market, Global, Licensing Deals By Geography, (%), 2004-2011
Figure 107: GBI Research Market Forecasting Model

Upcoming Reports:

Large Volume Parenteral (LVP) Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2019
By - Transparency Market Research
Parenteral formulations are sterile liquid or solid dosages (powder) packaged in either single or multi dose containers. Intended for administration by injection or infusion, parenteral preparations provide maximum bioavailability and efficacy than the oral dosage forms. Largely, parenteral preparations are classified based on their volume into small and large volume parenteral formulations. Small volume parenteral preparations are 100 ml or less and can be prepared as single dose or multiple dose product. On the other hand, large volume parenteral (LVP) preparations are more than 100 ml...
Technical and Advanced Structural Ceramics Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018
By - Transparency Market Research
Technical and advanced structural ceramics comprise of material that exhibits excellent physical properties under a demanding environment. The high melting point coupled with excellent chemical resistance adds to the application areas for the market. These ceramics find applications in a variety of products ranging from bioceramics to military.  The ceramics market can be segregated based on its application in wear and corrosion, cutting tools, air and aerospace, automotive, bioceramics, and armor and military applications. Based on geography, the market is...
Caustic Soda Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018
By - Transparency Market Research
Caustic soda, also known as sodium hydroxide or lye, is a non-flammable, odorless white solid. It is highly corrosive and is available in different forms like granules, pellets, and flakes. The process which is used to form chlorine, caustic soda, and soda ash is known as chlor-alkali. Caustic soda being a co-product of chlorine, the supply of caustic soda in the market depends significantly on the production of chlorine. Caustic soda has numerous applications, foremost of which is as a chemical base, where it acts as the vital raw material in the production of many organic...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Top End Stereo Systems Maker Harman Targets Chinese Auto Market
Apr 22, 2014  
Harman, the U.S.-based audio company that is best known as the provider of automobile stereos for top-end car models such as Mercedes-Benz, BMW and Ferrari, has said that it has signed agreements with two leading Chinese automakers—Chang’An and Geely. The company, that is associated with premium infotainment systems for leading auto makers, said that these new contracts...
Scientists Identify Cure for Dengue
Apr 18, 2014  
In a breakthrough discovery that can change the way dengue is treated, scientists have identified a drug target for the deadly dengue viruses. This discovery may help pave the way for discovery of vaccines that can cure this condition that affects nearly 390 million people throughout the world each year.  Scientists have used a new technique for this discovery to show that a region...
India is Facing a Cancer Crisis
Apr 15, 2014  
India is currently facing a cancer crisis – reports a recent research carried out at the King’s college London, in collaboration with the Tata Memorial Cancer Centre, Mumbai.  The reasons estimated for this crisis comprise of increasing rates of smoking, unequal access to proper treatment and belated diagnosis.  Every year, India witnesses around one...
Microparticle Tags to Check Counterfeit Goods Invented
Apr 14, 2014  
Researchers from the Massachusetts Institute of Technology have invented a new set of microparticles that can easily be read by smartphones and establish the authenticity of currency, electronic items and luxury goods.  This strategy is among those countless measures taken by big brands and companies to label their legitimate products in order to stop illegal copies of the...
USFDA Approves Lupins Generic Diabetic Drug
Apr 10, 2014  
The United States Food and Drugs Administration (USFDA) has finally approved Lupin Pharmaceuticals Inc (LPI), the American subsidiary of Indian drug manufacturers Lupin Ltd, to sell Pioglitazone Tablets in the U.S market. The approval has been granted first for fiscal 2015.  Pioglitazone is a generic medicine used for managing diabetes and is a version of Actos tablets...